Advanced

Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor

Standal, T; Borset, M; Lenhoff, S; Wisloff, F; Stordal, B; Sundan, A; Waage, A; Seidel, C; Turesson, Ingemar LU and Westin, Jan LU (2002) In Blood 100(12). p.3925-3929
Abstract
Insulinlike growth factor. 1 (IGF-1) has growth-promoting effects on myeloma cells in vitro as well as in vivo. In this study, we measured the concentration of IGF-1 and its major binding protein, IGF-binding protein 3 (IGFBP-3), in serum from 127 patients with multiple myeloma. Serum had been drawn at the time of diagnosis, before treatment With highdose melphalan. IGFBP-3 in myeloma patients (1.6 +/- 0.73 mug/mL; mean +/- SD) was significantly decreased compared to healthy age- and sex-matched controls (2.2 +/- 0.42 mug/mL). However, IGFBP-3 had no prognostic value in this study. The mean IGF-1 level did not differ between myeloma patients (17.8 +/- 7.7 nM) and controls (17.3 +/- 5.6 nM). Nevertheless, IGF-1 was a strong indicator of... (More)
Insulinlike growth factor. 1 (IGF-1) has growth-promoting effects on myeloma cells in vitro as well as in vivo. In this study, we measured the concentration of IGF-1 and its major binding protein, IGF-binding protein 3 (IGFBP-3), in serum from 127 patients with multiple myeloma. Serum had been drawn at the time of diagnosis, before treatment With highdose melphalan. IGFBP-3 in myeloma patients (1.6 +/- 0.73 mug/mL; mean +/- SD) was significantly decreased compared to healthy age- and sex-matched controls (2.2 +/- 0.42 mug/mL). However, IGFBP-3 had no prognostic value in this study. The mean IGF-1 level did not differ between myeloma patients (17.8 +/- 7.7 nM) and controls (17.3 +/- 5.6 nM). Nevertheless, IGF-1 was a strong indicator of prognosis. After 80 months of follow-up, myeloma patients with low levels (< 13 nM) of serum IGF-1 had not reached median survival. In the patient group with IGF-1 levels above 13 nM, median survival was 62 months (P =.006). These findings support the hypothesis of a role for IGF-1 in myeloma disease progression. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
100
issue
12
pages
3925 - 3929
publisher
American Society of Hematology
external identifiers
  • wos:000179453700010
  • pmid:12393395
  • scopus:0036892647
ISSN
1528-0020
DOI
10.1182/blood-2002-05-1406
language
English
LU publication?
yes
id
8cc6a8cd-c937-4cb9-9872-76cd085481a6 (old id 322877)
date added to LUP
2007-11-09 12:17:33
date last changed
2017-02-05 03:29:55
@article{8cc6a8cd-c937-4cb9-9872-76cd085481a6,
  abstract     = {Insulinlike growth factor. 1 (IGF-1) has growth-promoting effects on myeloma cells in vitro as well as in vivo. In this study, we measured the concentration of IGF-1 and its major binding protein, IGF-binding protein 3 (IGFBP-3), in serum from 127 patients with multiple myeloma. Serum had been drawn at the time of diagnosis, before treatment With highdose melphalan. IGFBP-3 in myeloma patients (1.6 +/- 0.73 mug/mL; mean +/- SD) was significantly decreased compared to healthy age- and sex-matched controls (2.2 +/- 0.42 mug/mL). However, IGFBP-3 had no prognostic value in this study. The mean IGF-1 level did not differ between myeloma patients (17.8 +/- 7.7 nM) and controls (17.3 +/- 5.6 nM). Nevertheless, IGF-1 was a strong indicator of prognosis. After 80 months of follow-up, myeloma patients with low levels (&lt; 13 nM) of serum IGF-1 had not reached median survival. In the patient group with IGF-1 levels above 13 nM, median survival was 62 months (P =.006). These findings support the hypothesis of a role for IGF-1 in myeloma disease progression.},
  author       = {Standal, T and Borset, M and Lenhoff, S and Wisloff, F and Stordal, B and Sundan, A and Waage, A and Seidel, C and Turesson, Ingemar and Westin, Jan},
  issn         = {1528-0020},
  language     = {eng},
  number       = {12},
  pages        = {3925--3929},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor},
  url          = {http://dx.doi.org/10.1182/blood-2002-05-1406},
  volume       = {100},
  year         = {2002},
}